Short-term LXR activation improves epidermal barrier features in mild-to-moderate atopic dermatitis: a randomized controlled trial

The prevalence of atopic dermatitis/AD has increased over the last decade to affect 17-24% of the children and 4-10% of the adults.1, 2 AD disease pathogenesis involves Th2/Th22 immune activation and barrier dysregulation.3-5 The epidermal barrier abnormalities in AD include defects in terminal differentiation (e.g., loricrin/LOR, filaggrin/FLG), tight junctions/TJ, lipids, S100As, antimicrobial peptides/AMPs and epidermal hyperplasia.6, 7 Compromised epidermal barrier also plays a major role in allergic sensitization, possibly leading to other atopic associations, including asthma, allergic rhinitis and food allergies.

http://ift.tt/2FUhVSv